NCT01710007View on ClinicalTrials.gov

Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia

PHASE3CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

November 30, 2012

Conditions
Hypercholesterolemia
Interventions
DRUG

1PC002

Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.

DRUG

Lipitor

Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.

Trial Locations (8)

112

Cheng Hsin General Hospital, Taipei

114

Tri-Service General Hospital, Taipei

231

Cardinal Tien Hospital, New Taipei City

333

Chang Gung Medical Foundation- LinKuo Branch, Taoyuan

11217

Taipei Veterans General Hospital, Taipei

23142

Buddhist Taipei TzuChi General Hospital, New Taipei City

23561

Taipei Medical University - Shuang Ho Hospital, New Taipei City

40705

Taichung Veterans General Hospital, Taichung

All Listed Sponsors
collaborator

Orient Europharma Co., Ltd.

INDUSTRY

lead

Orient Pharma Co., Ltd.

INDUSTRY

NCT01710007 - Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia | Biotech Hunter | Biotech Hunter